Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126909441 | 12690944 | 1 | I | 20160819 | 20160826 | 20160826 | EXP | GB-MYLANLABS-2016M1035383 | MYLAN | GOLDIE FC ET AL. CIPROFLOXACIN AND STATIN INTERACTION: A CAUTIONARY TALE OF RHABDOMYOLYSIS. BMJ CASE REP. 2016 | 0.00 | Y | 0.00000 | 20160826 | MD | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126909441 | 12690944 | 1 | PS | SIMVASTATIN. | SIMVASTATIN | 1 | Unknown | 40 MG, QD (NOCTE) | Y | U | 90868 | 40 | MG | QD | |||||
| 126909441 | 12690944 | 2 | I | CIPROFLOXACIN. | CIPROFLOXACIN | 1 | Unknown | UNK | U | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126909441 | 12690944 | 1 | Product used for unknown indication |
| 126909441 | 12690944 | 2 | Urinary tract infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126909441 | 12690944 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126909441 | 12690944 | Blood creatine phosphokinase increased | |
| 126909441 | 12690944 | Drug interaction | |
| 126909441 | 12690944 | Hepatic function abnormal | |
| 126909441 | 12690944 | Muscular weakness |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |